Back

SELLAS says SLS009 drives more than six-fold apoptosis versus daraxonrasib

Verifying
  • SELLAS reported SLS009 activity in MYC-amplified pancreatic cancer organoid models.
  • SLS009 produced 17.9% apoptosis versus 2.8% for daraxonrasib alone.
  • SELLAS presented the data at the AACR pancreatic cancer conference in San Diego.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.